Brief: Inhibikase Therapeutics Closes Up To $275 Million Financing
21/10/2024 16:32
Oct 21 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES CLOSING OF UP TO $275
MILLION
FINANCING AND ADVANCEMENT OF IKT-001PRO INTO A LATE STAGE
CLINICAL TRIAL IN PULMONARY ARTERIAL HYPERTENSION
Source text for Eikon: ID:nGNX7XvZzd
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share